Skip to main
  1. Stocks
  2. Equillium Inc
  3. Forecast
EQ

Equillium Inc (EQ) Stock Forecast & Price Target

Equillium Inc (EQ) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Equillium is supported by a compelling fundamental setup because EQ504 targets a biologically validated AhR pathway in ulcerative colitis, with human intestinal explant data showing dose-dependent CYP1A1 induction and a deep preclinical package across 14 models that supports barrier repair, anti-inflammatory signaling, and colon-targeted activity. The company’s lead program is differentiated by oral, colon-specific delivery and minimal systemic exposure, which helps address the safety tradeoffs that constrain S1P modulators, anti-TNFs, and JAK inhibitors while still targeting a large ~180K U.S. advanced-therapy UC population. Additional optionality comes from EQ302, but the investment case is anchored by EQ504 and could inflect further with Phase 1 initiation in mid-2026, biomarker data in 2Q27E, and a cash position of $61.3M funding operations into 2029.

Bears say

Equillium is a high-risk, early-stage biotechnology company whose value is heavily dependent on EQ504 producing clean Phase 1 evidence of target engagement and tolerability, yet the program has not entered human testing and the biomarker-to-efficacy bridge remains unproven. Its downside case is stark, with roughly $50M of residual cash translating to about $0.34 to $0.35 per share, while the need for a future $125M equity raise after positive data underscores meaningful dilution risk if results are negative or ambiguous. Even with $61.3M in cash as of March 31, 2026, competition from Azora Therapeutics, regulatory uncertainty, and persistent safety concerns such as PAH and class perception risk weaken the investment case.

Equillium Inc (EQ) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Equillium Inc and is not a guaranteed prediction by Public.com or investment advice.

Equillium Inc (EQ) Analyst Forecast & Price Prediction

Get the latest Equillium Inc (EQ) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Equillium Inc (EQ)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Equillium Inc (EQ) Forecast

Analysts have given Equillium Inc (EQ) a Strong Buy based on their latest research and market trends.

According to 5 analysts, Equillium Inc (EQ) has a Strong Buy consensus rating as of Nov 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Equillium Inc (EQ)


Equillium Inc (EQ) Analyst Forecast & Price Prediction

Get the latest Equillium Inc (EQ) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Equillium Inc (EQ)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover EQ stock data and trends